SCHEDULE: FMR LLC Boosts Stake in ATEA Pharmaceuticals to 6.7%
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson have reported a 6.7% beneficial ownership stake in ATEA Pharmaceuticals Inc. common stock as of June 30, 2025.
Summary
- FMR LLC and Abigail P. Johnson are reporting beneficial ownership of ATEA Pharmaceuticals Inc. common stock.
- The aggregate amount beneficially owned by FMR LLC and Abigail P. Johnson is 5,719,757.87 shares.
- This ownership represents 6.7% of the total outstanding common stock of ATEA Pharmaceuticals Inc.
- FMR LLC holds sole voting power over 5,717,317.00 shares and sole dispositive power over 5,719,757.87 shares.
- Abigail P. Johnson holds sole dispositive power over 5,719,757.87 shares.
- This filing is an Amendment No. 7 to a previously filed Schedule 13G.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine beneficial ownership disclosure (Schedule 13G) and does not contain information that would inherently indicate positive or negative sentiment regarding the company's operational or financial performance. It simply reports a significant stake by an institutional investor.
Future Outlook
NA
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
This filing indicates a significant institutional stake in ATEA Pharmaceuticals, a common occurrence for publicly traded pharmaceutical companies, reflecting investor interest in the sector.
Stakeholder Impact
- Shareholders: Provides transparency on significant institutional ownership, potentially signaling confidence from a major investor.
Key Dates
| Date | Description |
|---|---|
| 05/23/2023 | Effective date of Power of Attorney for Richard Bourgelas. |
| 08/08/2023 | Date of previous Schedule 13G filing by FMR LLC (accession number -23-002397) where Power of Attorney was incorporated by reference. |
| 06/30/2025 | Date of event which requires filing of this statement (reporting period end date). |
| 08/05/2025 | Date of signing and agreement for joint filing of this Schedule 13G. |
Recommendation
holdThis filing is a routine disclosure of beneficial ownership by a major institutional investor. While the significant stake held by FMR LLC and Abigail P. Johnson might be viewed as a vote of confidence, the filing itself does not provide sufficient financial or operational details about ATEA Pharmaceuticals Inc. to warrant a change in investment recommendation. Investors should consider this information in conjunction with the company's financial reports and strategic updates.
Keywords
ATEA Pharmaceuticals, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Schedule 13G, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.